LONG-TERM ALPRAZOLAM USE - ABUSE, DEPENDENCE OR TREATMENT

被引:0
|
作者
ROMACH, MK [1 ]
BUSTO, UE [1 ]
SOBELL, LC [1 ]
SOBELL, MB [1 ]
SOMER, GR [1 ]
SELLERS, EM [1 ]
机构
[1] UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Concern about persistent benzodiazepine use should be informed by data about reasons for such use. Consecutive long term alprazolam users (n = 25) admitted to an advertised outpatient program for discontinuation were characterized with respect to alprazolam use patterns and lifetime and current Axis I and II disorders. Patient characteristics were: females 50 percent; mean age, 46 +/- 12 yrs; prior medication use-benzodiazepines, 47 percent, anti-depressants, 23 percent; median duration of use 104 +/- 96 wks; median daily dose, 0.5 mg; continued effectiveness of alprazolam 50 percent. Over the duration of use patients shifted their initial pattern of use from as prescribed to a selfcontrolled "as required" basis (p < .05). Interviews using the Structured Clinical Interview for DSM-III-R (SCID) yielded diagnoses of DSM-III-R alprazolam dependence in all patients plus at least one additional psychiatric diagnosis in 65 percent (Axis I 65%; Axis II 39%). Most persistent alprazolam use does not represent abuse or addiction as usually understood. These data are most consistent with the interpretation that alprazolam is the most recent benzodiazepine used by patients to help control clinically important psychophathology and that most users make efforts to control or stop use.
引用
收藏
页码:391 / 395
页数:5
相关论文
共 50 条
  • [41] Long-Term Results of AMD Treatment with Use of Ranibizumab
    Wykrota, Halina
    Trzciakowski, Krzysztof
    OPHTHALMOLOGICA, 2014, 232 : 12 - 12
  • [42] Effective treatment of CLIPPERS with long-term use of rituximab
    Cipriani, Veronica P.
    Arndt, Nancy
    Pytel, Peter
    Reder, Anthony T.
    Javed, Adil
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (03):
  • [43] EFFECT OF WITHDRAWING TREATMENT AFTER LONG-TERM ADMINISTRATION OF ALPRAZOLAM, LORAZEPAM, OR PLACEBO IN PATIENTS WITH AN ANXIETY DISORDER
    COHN, JB
    NOBLE, EP
    PSYCHOPHARMACOLOGY BULLETIN, 1983, 19 (04) : 751 - 752
  • [44] Project Towards No Drug Abuse: Long-term substance use outcomes evaluation
    Sun, W
    Skara, S
    Sun, P
    Dent, CW
    Sussman, S
    PREVENTIVE MEDICINE, 2006, 42 (03) : 188 - 192
  • [45] LONG-TERM COMPARISON OF ALPRAZOLAM, LORAZEPAM AND PLACEBO IN PATIENTS WITH AN ANXIETY DISORDER
    COHN, JB
    WILCOX, CS
    PHARMACOTHERAPY, 1984, 4 (02): : 93 - 98
  • [46] Efficacy of Alprazolam monotherapy vs. Alprazolam plus Fluvoxamine in long term treatment for panic disorder
    Mihailescu, R
    Gherghel, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S55 - S56
  • [47] Predictors of Long-term Outcome of Opioid Dependence: Implications for Treatment Planning
    Weiss, Roger
    AMERICAN JOURNAL ON ADDICTIONS, 2017, 26 (03): : 238 - 238
  • [48] RISKS OF DEPENDENCE ON BENZODIAZEPINE DRUGS - A MAJOR PROBLEM OF LONG-TERM TREATMENT
    ASHTON, H
    BRITISH MEDICAL JOURNAL, 1989, 298 (6666): : 103 - 104
  • [50] Socioeconomic differences in adolescent substance abuse treatment participation and long-term outcomes
    Lui, Camillia K.
    Sterling, Stacy A.
    Chi, Felicia W.
    Lu, Yun
    Campbell, Cynthia I.
    ADDICTIVE BEHAVIORS, 2017, 68 : 45 - 51